After Maravoric was approved the other small molecole ccr5 inhibitors Vicriviroc, Cenicriviroc, and Aplaviroc eventually stop their HIV trials because of either safety concerns or not being able to improve on the current state of the art. If I remember correctly, I believe the 3 drug combo: Vicriviroc + 2 drugs was able to match haart without vicriviroc, but that still was not enough (since I assume Maravoric was already approved they didn't continue).

Unlike those, leronlimab is a monoclonal antibody, is a partial inhibitor, and not allosteric. Leronlimab has both a safety and efficacy advantage over maravoric and it is also a once a week injectable. Once leronlimab is approved, I don't see another ccr5 type inhibitor being able to improve upon the safety or efficacy with HIV. So it becomes much much harder for approval in my opinion .